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Abstract
Background: A previous systematic review reported that topical NSAIDs were effective in
relieving pain in acute conditions like sprains and strains, with differences between individual drugs
for efficacy. More trials, a better understanding of trial quality and bias, and a reclassification of
certain drugs necessitate a new review.
Methods: Studies were identified by searching electronic databases and writing to manufacturers.
We selected randomised double blind trials comparing topical NSAID with either placebo or
another active treatment in adults with acute pain, and extracted dichotomous information
approximating to a 50% reduction in pain at one week, together with details of adverse events and
withdrawals. Relative benefit and number-needed-to-treat (NNT), and relative risk and number-
needed-to-harm (NNH) were calculated, with sensitivity analyses where appropriate to investigate
differences between individual drugs and aspects of trial design.
Results: Twenty-six double blind placebo controlled trials had information from 2,853 patients for
evaluation of efficacy. Topical NSAID was significantly better than placebo in 19 of the 26 trials,
with a pooled relative benefit of 1.6 (95% confidence interval 1.4 to 1.7), and NNT of 3.8 (95%
confidence interval 3.4 to 4.4) compared with placebo for the outcome of half pain relief at seven
days. Results were not affected by outcome reported, or condition treated, but smaller trials
yielded a larger estimate of efficacy. Indirect comparisons of individual topical NSAIDs showed that
ketoprofen was significantly better than all other topical NSAIDs, while indomethacin was barely
distinguished from placebo. Three trials, with 433 patients, compared topical with oral NSAID (two
trials compared the same drug, one compared different drugs) and found no difference in efficacy.
Local adverse events, systemic adverse events, or withdrawals due to an adverse event were rare,
and no different between topical NSAID and placebo.
Conclusions: Topical NSAIDs were effective and safe in treating acute painful conditions for one
week.
Background
A systematic review of topical NSAIDs, conducted by this
research group in 1996, reported that they were effective
in relieving pain in acute conditions like sprains and
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of patients that need to be treated for one to benefit from
a particular drug, who would not have benefited from pla-
cebo, was used to estimate efficacy, and for all topical
NSAIDs pooled together the NNT at one week was 3.9
(95% confidence interval (CI) 3.4 to 4.4). There were dif-
ferences between individual topical NSAIDs, with
indomethacin being no different from placebo, while
ketoprofen (NNT 2.6), felbinac (NNT 3.0), ibuprofen
(NNT 3.5) and piroxicam (NNT 4.2) were all significantly
better than placebo.
There are three reasons why an updated review of topical
NSAIDs in acute pain is needed. First, we have a better
appreciation of factors that can introduce bias [2-4], and
would not now accept trials that were not double blind, or
were very small. Second, topical salicylate and benzydam-
ine are no longer classed as topical NSAIDs [5]. Thirdly,
there are now more trials. We believed that updating the
review would provide more accurate efficacy estimates for
topical NSAIDs, with a prior intent to determine efficacy
for individual drugs.
Methods
Searching
Relevant studies were sought regardless of publication
language, type, date or status. Studies included in the pre-
vious review were examined for inclusion in this updated
version, according to our inclusion criteria. The Cochrane
Library, MEDLINE and PreMedline, EMBASE and
PubMed were used to find relevant studies published
since the last review, for the years 1996 to April 2003. Ref-
erence lists of retrieved articles were also searched. The
search strategy included "application: topical" together
with "cream", "gel" etc, together with generic names of
NSAIDs, and proprietary preparations of topical treat-
ment in which the principal active ingredient was an
NSAID [6,7] (see Additional file 1: search strategy).
Twenty pharmaceutical companies in the UK, 66 in
Europe, and two in North America, known to manufac-
ture topical NSAIDs, were sent letters asking if they could
supply papers.
Selection
We identified reports of randomised, double-blind, active
or placebo-controlled trials in which treatments were
administered to adult patients with acute pain resulting
from any strains, sprains or sports injuries. Excluded con-
ditions were oral, ocular or buccal diseases. Application of
treatment had to be at least once daily. At least ten
patients had to be randomised to a treatment group. Out-
comes closest to seven days were extracted.
Quality and validity assessment
Trial quality was assessed using a validated three-item
scale with a maximum quality score of five [8]. Included
studies had to score at least two points, one for randomi-
sation and one for blinding. A sixteen-point scale was
used to assess trial validity [9].
Data abstraction
Quality and validity assessments were made independ-
ently by at least two reviewers. Extracted outcomes were
verified by one other reviewer. Disputes were settled by
discussion between all reviewers.
Outcomes
We defined our own outcome of clinical success, repre-
senting approximately a 50% reduction in pain [1]. This
was either the number of patients with a "good" or "excel-
lent" global assessment of treatment, or "none" or "slight"
pain on rest or movement (or comparable wording)
measured on a categorical scale. A hierarchy of outcomes
was used to extract efficacy information, shown below in
order of preference:
1) number of patients with a 50% or more reduction in
pain
2) patient reported global assessment of treatment
3) pain on movement
4) pain on rest or spontaneous pain
5) physician or investigator global assessment of
treatment
In addition, the number of patients showing undefined
"improvement" was also accepted.
Secondary outcomes were extracted from included papers
that reported them. These were the number of patients (i)
reporting one or more local adverse event (itching, sting-
ing, rash), (ii) reporting one or more systemic adverse
event (iii) withdrawing from trials due to adverse events.
Quantitative data synthesis
The number of patients randomised into each treatment
group (intention to treat) was used in the efficacy analysis.
Information was pooled for the number of patients in
each trial achieving at least 50% pain relief, or similar
measure, for both topical NSAID and control. These were
used to calculate NNT with a 95% confidence interval (CI)
[10]. Relative benefit and relative risk estimates with 95%
CIs were calculated using the fixed effects model [11]. A
statistically significant benefit of topical NSAID over con-
trol was assumed when the lower limit of the 95% CI ofPage 2 of 9
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nificant benefit of control over active treatment was
assumed when the upper limit of the 95% CI was less than
one. Number-needed-to-harm (NNH) and relative risk
were calculated for these outcomes in the same way as for
NNTs and relative benefit. Homogeneity of trials was
assessed visually [12-14]. All calculations were performed
using Microsoft Excel X for the Macintosh and RevMan
4.2. In sensitivity analyses the z test was used [15].
QUOROM guidelines were followed [16].
Sensitivity analysis
Our prior intention was to perform sensitivity analyses on
pooled outcomes using the z test in terms of quality score
(less than 2 versus 3 or more), validity score (less than 8
versus 9 or more), size (less than 40 patients per group
versus 40 or more, the median in a previous meta-analysis
[1]), outcome type (higher versus lower preference out-
comes), and particular NSAID used. At least three studies
had to be available in any of these different contexts
before information was pooled.
Results
Study characteristics
Ten out of the 20 UK companies, and two out of 66 Euro-
pean companies that we contacted replied to our request
for studies. However, only three companies supplied us
with useful material; either published studies or bibliog-
raphies. One company supplied material that was unpub-
lished at the time of writing [17].
We identified 89 potential papers from our searches. Fifty-
three were excluded (see Additional file 2: studies
excluded from the review, Additional file 3: QUOROM
flow diagram). Of the original 89, 64 papers were in the
previous review, of which we excluded 30; four placebo
and 15 active controlled trials used salicylates, four pla-
cebo controlled trials used benzydamine, two were single
blind, and one each had inappropriate randomisation,
did not state dose or duration of treatment, had no usea-
ble data, used mixed pain conditions including some
chronic conditions, or had an inappropriate add-on
design. There were 25 potential papers not in the previous
review. Of these, 23 were excluded because they were not
randomised (9), had no useable data (4), were not double
blind (3), were experimental (2), or for other reasons (5).
Thirty-six trials met the selection criteria; 34 from the pre-
vious review and two new ones. Twenty-four trials [17-40]
had only placebo controls, eight [41-48] only active con-
trols, and four [49-52] had both placebo and active con-
trols. Of the 12 active controlled trials, nine compared
one topical NSAID with a different topical NSAID, and
three [44,48,49] used oral NSAID controls. Details of all
included studies with outcomes and quality and validity
scores are in Additional files 4 (Outcome details of pla-
cebo-controlled trials) and 5 (Outcome details of active-
controlled trials). Information about patients was limited,
though age ranges were given. Patients had mainly sports
injuries, soft tissue injuries, or sprains and strains.
Quality scores were high, with 24/28 placebo controlled
and 11/12 active controlled trials scoring 3 or more points
out of a maximum of 5. Validity scores were also high,
with 25/28 placebo controlled and 10/12 active control-
led trials scoring 9 or more out of a maximum of 16 (see
Additional files 4 and 5).
Placebo controlled trials
Efficacy
Twenty-six trials with information from 2,853 patients
were analysed for efficacy. In 19 of the 26 trials topical
NSAID was significantly better than placebo, with a lower
confidence interval of the relative benefit above 1 in our
analysis. Topical NSAIDs as a class were significantly bet-
ter than placebo, with relative benefit 1.6 (95% CI 1.4 to
1.7) and NNT 3.8 (3.4 to 4.4) (Table 1). Mean response
rate with placebo was 39% and varied from 8% to 75% in
individual trials. Mean response rate with topical NSAID
was 65%, varying from 41% to 100% in individual trials
(Figure 1).
Sensitivity analyses could not be done for higher versus
lower quality or validity scores, because there were few
studies of lower quality (2/5 on the quality scale) or lower
validity (8/16 or less on the validity scale). Analysis lim-
ited to only higher quality or higher validity trials, or trials
of both higher quality and higher validity, produced no
difference in the efficacy measure (Table 1). The median
group size for topical NSAID was 41. There was a signifi-
cantly better (lower) NNT in trials with fewer than 40
patients in each treatment arm than in those with 40
patients or more (z = 3.3, p = 0.001). Outcomes of unde-
fined improvement and physician rated global outcomes
gave the same NNT as our preferred outcomes of patient
rated global or pain on movement/spontaneous pain.
Efficacy estimates were also made for five individual drugs
studied in at least three trials (Table 1). The five topical
NSAIDs were all significantly better than placebo, but in
the case of indomethacin just so. Ketoprofen had the low-
est (best) NNT of 2.6 (2.2 to 3.3). The result for ketopro-
fen was significantly better than for ibuprofen (z = 2.2, p
= 0.03), felbinac (z = 2.1, p = 0.03), piroxicam (z = 3.0, p
= 0.003) and indomethacin (z = 4.5, p < 0.00006).
Harm
There was no statistically significant difference between
the numbers of patients experiencing one or more local
adverse events (4%), one or more systemic adverse eventsPage 3 of 9
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adverse event (0.8%), with topical NSAIDs than with pla-
cebo (Table 1). For systemic adverse events, 56 of the 70
events recorded occurred in a single trial [27], and the rate
of systemic adverse events excluding this trial was below
1%. Systemic adverse events and adverse event withdraw-
als did not differ between topical and oral NSAID.
Active controlled trials
Three trials, with 433 patients, compared a topical NSAID
with an oral NSAID (indomethacin 75 mg daily in one
trial and ibuprofen 1,200 mg daily in two). One trial [44]
compared different topical and oral NSAIDs (felbinac
foam with oral ibuporofen), while the other two com-
pared the same topical and oral NSAID, ibuprofen in one
[48] and indomethacin in the other [49]. Overall rates of
treatment success were similar for topical NSAID (57%)
and oral NSAID (62%), with no statistically significant
difference (relative benefit 0.9; 0.8 to 1.1).
The other nine trials compared one topical preparation
with another (see Additional file 5), For only topical
piroxicam 0.5% compared with topical indomethacin 1%
was there at least three trials (with 716 patients). Piroxi-
cam was significantly more effective than indomethacin,
with improvement in 52% on piroxicam and 39% on
indomethacin. The relative benefit was 1.3 (1.1 to 1.5)
and the NNT for piroxicam compared with indomethacin
Table 1: Summary data and sensitivity analyses for placebo controlled trials
Success with
Parameter Trials Patients treatment placebo Relative benefit 
(95% CI)
NNT (95% CI)
All trials 26 2853 993/1531 512/1322 1.6 (1.4 to 1.7) 3.8 (3.4 to 4.4)
Trial quality
Quality score ≥3/5 23 2551 893/1375 443/1176 1.6 (1.5 to 1.8) 3.7 (3.2 to 4.3)
Validity score ≥9/
16
24 2793 969/1501 508/1292 1.5 (1.4 to 1.7) 4.0 (3.5 to 4.6)
Quality score ≥3 
and validity score 
≥9
22 2511 876/1355 440/1156 1.6 (1.4 to 1.8) 3.8 (3.3 to 4.4)
Trial size
≥40 patients 
per group
15 2279 761/1234 400/1045 1.4 (1.3 to 1.6) 4.3 (3.7 to 5.2)
<40 patients 
per group
11 574 232/297 112/277 1.9 (1.6 to 2.2) 2.7 (2.2 to 3.3)
Efficacy by 
outcome type
preferred 
outcomes
17 1941 676/1025 373/916 1.5 (1.3 to 1.6) 4.0 (3.4 to 4.8)
lower 
prefernce 
outcomes
9 912 317/506 139/406 1.7 (1.5 to 2.1) 3.5 (2.9 to 4.5)
Efficacy by 
topical NSAID
ketoprofen 6 517 203/261 101/256 2.1 (1.7 to 2.5) 2.6 (2.2 to 3.3)
ibuprofen 5 365 112/183 67/182 2.0 (1.5 to 2.6) 4.1 (2.9 to 6.9)
felbinac 3 413 112/210 57/203 1.6 (1.2 to 2.2) 4.0 (2.9 to 6.2)
piroxicam 3 563 179/283 118/280 1.4 (1.1 to 1.7) 4.7 (3.4 to 7.7)
indomethacin 3 394 95/197 76/197 1.3 (0.99 to 1.6) 10 (5.2 to infinity)
Adverse events NNH 95% CI
Local adverse 
events
23 2741 65/1464 60/1277 1.6 (1.0 to 2.5) Not calculated
Systemic adverse 
events
23 2685 40/1437 30/1248 1.4 (0.9 to 2.0) Not calculated
Adverse events 
withdrawals
24 3011 13/1601 10/1410 1.6 (0.8 to 3.4) Not calculatedPage 4 of 9
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with piroxicam (2%) than with indomethacin (10%). The
relative risk for an adverse event with piroxicam was 0.2
(0.1 to 0.5) compared with indomethacin, and the
number needed to prevent one local adverse event was 14
(9 to 26).
Discussion
The original review [1], and this updated one, concluded
that topical analgesics were effective in acute conditions.
Despite removing trials of lower quality, and topical
agents that are not now regarded as topical NSAIDs, the
NNT for all topical NSAIDs compared with placebo for
the outcome equivalent to at least half pain relief at seven
days was 3.8 (3.4 to 4.4). The previous review gave an
NNT of 3.9 (3.4 to 4.4). Three trials comparing topical
with oral NSAID found no difference in efficacy.
What are the limitations of this review that might ques-
tion this demonstration of efficacy? The included trials
spanned several decades, and retrospective examination
finds fault with them in several respects. Trials were often
small. Small size can lead to the influence of chance
effects on treatment and placebo event rates [4]. Different
preparations were used, with different application sched-
ules, concentrations of active agent, and formulations.
Outcomes in the trials were not consistent, and a hierar-
chy of outcomes had to be constructed. Some clinical
Randomised double-blind studies of topical NSAID compared to topical placebo for one-week outcome of successful treatmentFigure 1
Randomised double-blind studies of topical NSAID compared to topical placebo for one-week outcome of successful treat-
ment. Inset scale shows size of individual trials.
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patients in the trials were similar, with similar conditions,
when trial designs included both randomisation and dou-
ble-blinding, and when the duration of trials was
appropriate.
We addressed these limitations with pre-planned sensitiv-
ity analyses. Using only studies with higher quality and
validity scores, or studies with higher rather than lower
preference outcomes made no difference (preferred out-
comes were patient rated global or pain, lower preference
undefined improvement and physician rated global out-
comes). Trial size had an important effect, with smaller
trials having a lower (better) NNT. The evidence was that
topical NSAIDs were effective whatever strategy was used
for sensitivity analysis, improving the robustness of the
overall result.
Different NSAIDs had different efficacy, with ketoprofen
being significantly better than all others in an indirect
comparison, while indomethacin was barely distin-
guished from placebo. The only direct comparison of top-
ical preparations where there was an adequate amount of
information to pool (three trials and 716 patients) was for
topical piroxicam compared with topical indomethacin.
Topical piroxicam was significantly more effective than
topical indomethacin, supporting the indirect
comparison.
A possible criticism might be that there has been selective
publication of trials showing topical NSAIDs to be effec-
tive, and suppression of trials where there was no
difference between topical NSAID and placebo. Funnel
plots do not reliably detect publication bias [13,14], so we
did not use them or make any adjustment for possible
publication bias [53]. We did approach every company in
the world that we could identify as being involved with
topical NSAID manufacture or sale for any additional
unpublished trials. No more unpublished material was
identified than in the original review [1]. When unpub-
lished material is found, it often does not change the rel-
evance of a result [54-56].
It is important to emphasise that both active and placebo
treatments were rubbed on, making any effect of rubbing
equal in both groups. It's not just the rubbing! The aver-
age placebo response in the included trials was 39%, com-
pared with the average response of 65% with topical
NSAID. The response with placebo is consistent with that
found in painful conditions using a variety of conditions
and endpoints [57].
While there may be reservations about the quality and
amount of information available for topical NSAIDs in
acute conditions, the comparison with NSAIDs in other
conditions is favourable. For instance, in dysmenor-
rhoeas, a Cochrane review of NSAIDs [58] included 4,066
women, but the trials themselves were small, with an aver-
age of about 50 per trial. These 63 randomised double-
blind trials investigated 21 different NSAIDS, each at dif-
ferent doses, in studies of varying design, varying out-
comes, and varying duration. Two Cochrane reviews of
NSAIDs for osteoarthritis in hip and knee [59,60] had
only 3,000 patients in 29 trials.
One implication of short duration studies is that they will
not capture important long-term safety information. This
may be important for ongoing applications of gels, creams
or sprays. There is, however, information that indicates
that topical NSAIDs do not cause the gastrointestinal
harm found with oral NSAIDs [61], nor are they associ-
ated with increased renal failure [62].
Clearly there is a body of evidence to support the efficacy
of topical NSAIDs in acute painful conditions. The evi-
dence of efficacy remains despite removing smaller stud-
ies lacking double blinding that are open to bias, and
substituting newer, larger trials of high quality.
Conclusions
Topical NSAIDs were effective and safe in treating acute
painful conditions for one week.
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